Research & Analysis

September 21, 2020

As a part of the Premarket Tobacco Product Application process, Juul Labs has built up its science and evidence-based capabilities with a comprehensive research program focused on examining the public health impact of JUUL System. Juul Labs today announced findings from its science and research program at the 3rd Scientific Summit on Tobacco Harm Reduction, which was held virtually. The studies presented covered a wide range of topics that contribute to the growing body of scientific evidence on ENDS products, including information on the nicotine delivery profile of the JUUL System compared to cigarettes as well as rates of complete switching to the JUUL System among adult smokers.

Below is the full list of studies presented by Juul Labs:

  • Switching Among Adult Smokers who Purchased the JUUL System: 12-Month Follow-Up Results from Two Large Longitudinal Studies 
  • Differences in Rates of Adult Smokers Switching Away from Smoking Using JUUL System Products, Across Jurisdictions with Different Maximum Nicotine Concentrations (North America and the United Kingdom)
  • Nicotine Pharmacokinetic and Subjective Effect Assessment of the JL Electronic Nicotine Delivery System with Three Nicotine Concentrations Relative to Combustible Cigarettes in Adult Smokers
  • Comparative Health Risk Assessment of JUUL System and Combustible Cigarette 
  • The Impact of Banning ENDS Products on Combustible Cigarette Sales: Initial Evidence from U.S. State-Level Policies
  • Dependence on JUUL System ENDS is Lower than Cigarette Dependence: Adults and Youth

In addition to the six posters Juul Labs presented, two independent contract research organizations presented studies sponsored by Juul Labs:

  • Modeling Potential Health Gains and Health System Savings Associated With Vaporized Nicotine Products In Canada (presented by AppEco). 
  • Estimates of the Population’s Use of the JUUL Electronic Nicotine Delivery System May Vary Between Survey Questions That Are Accompanied and Unaccompanied by an Image of the JUUL Device (presented by the Centre for Substance Use and Research)

Juul Labs is fully committed to the Premarket Tobacco Product Application process in the United States, and to that end has built a robust scientific research program to help assess the harm-reduction potential of JUUL products, including their impact on the individual user, their ability to move adult smokers away from combustible cigarettes, and the net-population impact on public health. 

The Company is committed to working cooperatively with regulators, public health officials, and other stakeholders to preserve the historic opportunity to transition adult smokers away from combustible cigarettes, while combating underage use.

Juul Labs will continue to share results from its science and research program transparently with the public health communities as it works to support the scientific basis for the category, as well as future regulatory filings.